Trueblood Wealth Management LLC Buys 882 Shares of Stryker Co. (NYSE:SYK)

Trueblood Wealth Management LLC boosted its stake in Stryker Co. (NYSE:SYK) by 28.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,022 shares of the medical technology company’s stock after acquiring an additional 882 shares during the period. Trueblood Wealth Management LLC’s holdings in Stryker were worth $1,497,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Elefante Mark B bought a new stake in shares of Stryker in the 4th quarter valued at $337,000. Metis Global Partners LLC raised its stake in Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after buying an additional 1,561 shares during the last quarter. Fred Alger Management LLC lifted its holdings in Stryker by 415.8% in the fourth quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company’s stock valued at $8,664,000 after buying an additional 19,356 shares during the period. US Bancorp DE boosted its position in Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock valued at $65,829,000 after acquiring an additional 976 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in Stryker by 5.0% during the fourth quarter. Larson Financial Group LLC now owns 10,294 shares of the medical technology company’s stock valued at $3,706,000 after acquiring an additional 492 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SYK shares. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Citigroup reaffirmed a “buy” rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. BTIG Research set a $403.00 target price on Stryker and gave the stock a “buy” rating in a report on Monday, April 14th. Evercore ISI dropped their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $427.30.

Stryker Stock Performance

Shares of SYK stock opened at $385.21 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $370.53 and a two-hundred day simple moving average of $375.91. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market capitalization of $147.03 billion, a PE ratio of 49.64, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.50 earnings per share. Analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is currently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.